Table 1.
Baseline demographics
| Risedronate Group (n=20) | Control Group (n=22) | P Value | |
|---|---|---|---|
| Male, n (%) | 11 (55) | 16 (72) | |
| Age (yr) | 42±11 | 48±14 | |
| men | 45.7±11 (34–69) | 47.7±15 (25–68) | 0.72 |
| women | 37.7±11 (22–54) | 50.3±9 (40–62) | 0.03 |
| BMI (kg/m2) | 24±4 | 27±5 | 0.03 |
| men | 25.1±4 | 26.7±5 | 0.38 |
| women | 22.8±3 | 30.3±3 | 0.003 |
| BSA (m2) | 1.76±0.2 | 1.94±0.2 | 0.02 |
| men | 1.90±0.2 | 1.97±0.2 | 0.39 |
| women | 1.58±0.2 | 1.84±0.2 | 0.03 |
| Race | |||
| African American | 3 | 3 | |
| Hispanic | 10 | 11 | |
| white | 5 | 6 | |
| other | 2 | 2 | |
| Dialysis (mo) | 11 (6–66) | 12 (6–35) | 0.72 |
| ESRD etiology | |||
| hypertensive nephrosclerosis | 6 | 7 | |
| diabetic nephropathy | 3 | 6 | |
| chronic GN | 10 (2 males) | 5 (4 males) | |
| adult polycystic kidney disease | 1 | 2 | |
| other | 0 | 2 | |
Continuous variable are presented as mean ± SD if normally distributed or median (interquartile range) if not normally distributed.